We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · June 14, 2021

Pembrolizumab Plus Chemoradiation in Unresectable, Locally Advanced, Stage III NSCLC

JAMA Oncology

 

Additional Info

JAMA Oncology
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial
JAMA Oncol 2021 Jun 04;[EPub Ahead of Print], SK Jabbour, KH Lee, N Frost, V Breder, DM Kowalski, T Pollock, E Levchenko, N Reguart, A Martinez-Marti, B Houghton, JB Paoli, S Safina, K Park, T Komiya, A Sanford, V Boolell, H Liu, A Samkari, SM Keller, M Reck

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading